Literature DB >> 11502729

Genetic polymorphism of cytochrome P450 3A5 in Chinese.

F C Chou1, S J Tzeng, J D Huang.   

Abstract

The CYP3A subfamily enzymes are the most abundant and important drug-metabolizing enzymes. Wide variation in the CYP3A5 expression was well known. Recently, G(-44) to A of CYP3AP1 was found to segregate with CYP3A5*3 defective allele. The homozygous A(-44) subjects showed low expression of CYP3A5. In Caucasian, only 9.2% of CYP3AP1 alleles were with G(-44) and associated with the wild-type CYP3A5*1 allele, which expressed CYP3A5 significantly. By using polymerase chain reaction and FauI endonuclease digestion, we found that 28% of CYP3AP1 alleles are G(-44) in 110 Chinese subjects. The frequency is 3 times higher in Chinese than in Caucasian, implying more Chinese subjects are probably extensive CYP3A5 metabolizers. In two Chinese subjects, we also found a heterozygous G(13048)gt-to-G(13048)gc mutation at the intron 5 splicing donor site, leading to a splicing defect. A 6478-base pair minigene, including intron 4 to intron 7, was used for in vitro transcription. Both the wild-type and the mutated minigenes produced splicing variants. The wild-type minigene used Ggt(13050) as the splicing donor. The mutant minigene used gt(8504) in intron 4 or gt(13112) in intron 5 as the splicing donor for various splicing acceptors. The splicing defect may result in a shorter peptide or cause the frame shift. In the other two Chinese subjects, we found A(14763)-to-G mutation in exon 7, resulting in the Q200R amino acid change. The consequence of the polymorphism site has not been known. In Caucasian, there is a reported T398N polymorphism. In these Chinese subjects, we did not find polymorphism at this site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502729

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.

Authors:  Yuanyuan Dong; Huasheng Xiao; Qi Wang; Chunxiu Zhang; Xiuming Liu; Na Yao; Haihui Sheng; Haiyan Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

Review 4.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system.

Authors:  Su-Jun Lee; Ilse P van der Heiden; Joyce A Goldstein; Ron H N van Schaik
Journal:  Drug Metab Dispos       Date:  2006-10-11       Impact factor: 3.922

Review 6.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 8.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

9.  CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.

Authors:  Yanhui Lu; Edward J Fuchs; Craig W Hendrix; Namandjé N Bumpus
Journal:  Drug Metab Dispos       Date:  2014-08-12       Impact factor: 3.922

10.  Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India.

Authors:  Ranjana Singh; Aneesh Srivastava; Rakesh Kapoor; Raj K Sharma; Rama D Mittal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-04-03       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.